None
Quote | Bioinvent Ab (OTCMKTS:BOVNF)
Last: | $4.70 |
---|---|
Change Percent: | 100.0% |
Open: | $0 |
Close: | $4.70 |
High: | $0 |
Low: | $0 |
Volume: | 14 |
Last Trade Date Time: | 12/31/1969 07:00:00 pm |
News | Bioinvent Ab (OTCMKTS:BOVNF)
LUND, SWEDEN / ACCESSWIRE / July 22, 2024 / BioInvent International (STO:BINV) Two posters to be presented on early clinical projects from BioInvent's robust pipeline totaling six clinical programs: Progress with the Phase 1 trial studying BI-1910 as single agent in solid tumors Initial...
LUND, SE / ACCESSWIRE / July 17, 2024 / BioInvent International (STO:BINV) Agreement to support expansion of BI-1607 program with new Phase 2 triplet combination study in metastatic melanoma The study will evaluate anti-FcγRIIB antibody BI-1607 with low-dose anti-CTLA-4, ipilimu...
Message Board Posts | Bioinvent Ab (OTCMKTS:BOVNF)
Subject | By | Source | When |
---|---|---|---|
Transgene and BioInvent Announce Clinical Trial Collaboration and | ancientacid | investorshub | 06/28/2022 8:02:31 PM |
Exelixis-BioInvent Establish Immuno-Oncology Pact | ancientacid | investorshub | 06/17/2022 7:28:22 PM |
The global non-Hodgkin lymphoma treatment market size is | ancientacid | investorshub | 01/28/2021 11:17:25 PM |
BioInvent Phase I/IIa data suggest BI-1206 restores activity | ancientacid | investorshub | 01/28/2021 2:31:32 PM |
BioInvent secures $3M on selection of antibodies under | ancientacid | investorshub | 01/28/2021 2:29:19 PM |
News, Short Squeeze, Breakout and More Instantly...
LUND, SWEDEN / ACCESSWIRE / July 22, 2024 / BioInvent International (STO:BINV) Two posters to be presented on early clinical projects from BioInvent's robust pipeline totaling six clinical programs: Progress with the Phase 1 trial studying BI-1910 as single agent in solid tumors Initial...
LUND, SE / ACCESSWIRE / July 17, 2024 / BioInvent International (STO:BINV) Agreement to support expansion of BI-1607 program with new Phase 2 triplet combination study in metastatic melanoma The study will evaluate anti-FcγRIIB antibody BI-1607 with low-dose anti-CTLA-4, ipilimu...
Model-informed approach supporting dose selection and optimization of clinical development Confirming wide potential dose-range of BI-1808 in the continued clinical evaluation which already has shown promising single agent safety and efficacy Poster to be presented at PAGE 2024 to be ...